Extracorporeal Life Support in "Awake" Patients as a Bridge to Lung Transplant.
BACKGROUND
Traditionally, patients on extracorporeal membrane oxygenation (ECMO) are sedated and mechanically ventilated, which increases risk of complications related to immobility and mechanical ventilation. The purpose of this study was to assess the feasibility and highlight the benefits of a bridge to lung transplant (LTx) using "awake ECMO" support.


METHODS
The peripheral venovenous or venoarterial ECMO was implanted at a bedside. A retrospective study of patients undergoing LTx between January 2007 and March 2013 was performed. Outcomes in patients supported on ECMO as a bridge to LTx and kept "awake" (Group 1) were compared with the rest of the LTx patients (Group 2).


RESULTS
In this period, 249 LTx were performed and in them 7 patients were bridged to LTx using "awake ECMO" strategy. Two patients were awake at ECMO implantation and throughout the therapy, and two patients were on ventilator support at the time of ECMO implantation who were extubated later and maintained awake until LTx. The remaining three patients were awake for some time during the ECMO. There was no statistically significant difference in most donor characteristics and recipient baseline characteristics as well as post-LTx parameters between the two groups. One-year survival estimate was not different between the groups: Group 1, 85.7% vs. Group 2, 86.3% (log rank p = 0.99).


CONCLUSIONS
In end-stage lung disease, the ECMO can be commenced in "awake" patients and patients can be awakened on ECMO. The "awake ECMO" strategy may avoid complications related to mechanical ventilation, sedation, and immobilization and provide comparable outcomes in the high-risk LTx patients.
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Prashant N
PN
Mohite
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Anton
A
Sabashnikov
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Anna
A
Reed
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Diana G
DG
Saez
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Nikhil P
NP
Patil
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Aron-Frederik
AF
Popov
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Fabio
F
DeRobertis
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Toufan
T
Bahrami
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Mohamed
M
Amrani
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Martin
M
Carby
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Sundip
S
Kaul
Department of Cardiothoracic Transplantation and Mechanical Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.
Andre R
AR
Simon
D000328:Adult; D015199:Extracorporeal Membrane Oxygenation; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007103:Immobilization; D053208:Kaplan-Meier Estimate; D008168:Lung / Q000503:physiopathology / Q000601:surgery*; D008171:Lung Diseases / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D016040:Lung Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012121:Respiration, Artificial; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014850:Waiting Lists; D014851:Wakefulness; D055815:Young Adult
D006993:Hypnotics and Sedatives